<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04651088</url>
  </required_header>
  <id_info>
    <org_study_id>STU-2020-0587</org_study_id>
    <nct_id>NCT04651088</nct_id>
  </id_info>
  <brief_title>Comparing Alkalinizing Agents Efficacy on Stone Risk in Patients on a Metabolically Controlled Diet</brief_title>
  <official_title>Evaluation of Multiple Alkalinizing Agents on Urinary Stone Risk Parameters in Stone and Non-stone Formers on a Metabolically Controlled Diet</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare over the counter and alternative prescription urinary&#xD;
      alkalinizing agents to slow release potassium citrate in their ability to modify urinary&#xD;
      parameters associated with stone formation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Kidney stones are a common medical problem, occurring in almost 10% of people in the United&#xD;
      States1. Furthermore, 50% of patients will recur within 10 years2. Metabolic testing is&#xD;
      advised in recurrent stone formers, as well as those considered high risk, to assess for a&#xD;
      specific abnormality which may prompt intervention to prevent future stone formation.&#xD;
      Non-surgical interventions include both dietary counselling, as well as pharmacotherapy.&#xD;
&#xD;
      One of the most commonly prescribed class of pharmacotherapies is alkali therapy which can be&#xD;
      used to both increase the urinary pH and raise the urine citrate levels. This is particularly&#xD;
      useful as correction of very acidic urinary pH (&lt;5.5) can counteract uric acid&#xD;
      crystallization thereby preventing or even dissolving uric acid stones3. Further, citrate has&#xD;
      been shown to be a potent inhibitor of calcium stones by binding to the calcium directly4 and&#xD;
      inhibiting crystal nucleation, thereby reducing calcium stone formation5,6.&#xD;
&#xD;
      The most commonly utilized preparation of alkali therapy is potassium citrate which has been&#xD;
      shown to prevent stone formation better than sodium citrate7. Unfortunately, some forms of&#xD;
      potassium citrate (crystal packets) have become unavailable, and the slow release form of&#xD;
      potassium citrate (UroCit-K) now exceeds $15/day in cost8. There have been multiple&#xD;
      alternative alkali therapies that have been used in place of potassium citrate, including&#xD;
      both medical foods and prescription medications, but with little evidence to support their&#xD;
      use. A pilot study in order to quantify the metabolic effects of these agents and compare&#xD;
      them to potassium citrate will be performed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24 hour urine volume</measure>
    <time_frame>Change from baseline (Day 4) to initial start on treatment (Day 5)</time_frame>
    <description>Total urine volume</description>
  </primary_outcome>
  <primary_outcome>
    <measure>24 hour urine volume</measure>
    <time_frame>Change from baseline (Day 4) to end of study (day 12)</time_frame>
    <description>Total urine volume</description>
  </primary_outcome>
  <primary_outcome>
    <measure>24 hour urine creatinine</measure>
    <time_frame>Change from baseline (Day 4) to initial start on treatment (Day 5)</time_frame>
    <description>Urine creatinine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>24 hour urine creatinine</measure>
    <time_frame>Change from baseline (Day 4) to end of study (day 12)</time_frame>
    <description>Urine creatinine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>24 hour urine calcium</measure>
    <time_frame>Change from baseline (Day 4) to initial start on treatment (Day 5)</time_frame>
    <description>urine calcium</description>
  </primary_outcome>
  <primary_outcome>
    <measure>24 hour urine calcium</measure>
    <time_frame>Change from baseline (Day 4) to end of study (day 12)</time_frame>
    <description>urine calcium</description>
  </primary_outcome>
  <primary_outcome>
    <measure>24 hour urine potassium</measure>
    <time_frame>Change from baseline (Day 4) to initial start on treatment (Day 5)</time_frame>
    <description>Urine potassium</description>
  </primary_outcome>
  <primary_outcome>
    <measure>24 hour urine potassium</measure>
    <time_frame>Change from baseline (Day 4) to end of study (day 12)</time_frame>
    <description>Urine potassium</description>
  </primary_outcome>
  <primary_outcome>
    <measure>24 hour urine sodium</measure>
    <time_frame>Change from baseline (Day 4) to initial start on treatment (Day 5)</time_frame>
    <description>Urine sodium</description>
  </primary_outcome>
  <primary_outcome>
    <measure>24 hours urine sodium</measure>
    <time_frame>Change from baseline (Day 4) to end of study (day 12)</time_frame>
    <description>Urine sodium</description>
  </primary_outcome>
  <primary_outcome>
    <measure>24 hours urine citrate</measure>
    <time_frame>Change from baseline (Day 4) to initial start on treatment (Day 5)</time_frame>
    <description>Urine citrate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>24 hours urine citrate</measure>
    <time_frame>Change from baseline (Day 4) to end of study (day 12)</time_frame>
    <description>Urine citrate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>24 hours urine uric acid</measure>
    <time_frame>Change from baseline (Day 4) to initial start on treatment (Day 5)</time_frame>
    <description>Urine uric acid</description>
  </primary_outcome>
  <primary_outcome>
    <measure>24 hours urine uric acid</measure>
    <time_frame>Change from baseline (Day 4) to end of study (day 12)</time_frame>
    <description>Urine Uric Acid</description>
  </primary_outcome>
  <primary_outcome>
    <measure>24 hours urine oxalate</measure>
    <time_frame>Change from baseline (Day 4) to initial start on treatment (Day 5)</time_frame>
    <description>Urine oxalate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>24 hours urine oxalate</measure>
    <time_frame>Change from baseline (Day 4) to end of study (day 12)</time_frame>
    <description>Urine oxalate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>24 hours urine magnesium</measure>
    <time_frame>Change from baseline (Day 4) to initial start on treatment (Day 5)</time_frame>
    <description>Urine magnesium</description>
  </primary_outcome>
  <primary_outcome>
    <measure>24 hours urine magnesium</measure>
    <time_frame>Change from baseline (Day 4) to end of study (day 12)</time_frame>
    <description>Urine magnesium</description>
  </primary_outcome>
  <primary_outcome>
    <measure>24 hours urine ammonia</measure>
    <time_frame>Change from baseline (Day 4) to initial start on treatment (Day 5)</time_frame>
    <description>Urine ammonia</description>
  </primary_outcome>
  <primary_outcome>
    <measure>24 hours urine ammonia</measure>
    <time_frame>Change from baseline (Day 4) to end of study (day 12)</time_frame>
    <description>Urine ammonia</description>
  </primary_outcome>
  <primary_outcome>
    <measure>24 Hour Urine pH</measure>
    <time_frame>Change from baseline (Day 4) to initial start on treatment (Day 5)</time_frame>
    <description>Overal Urine pH from 24h urine sample.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>24 Hour Urine pH</measure>
    <time_frame>Change from baseline (Day 4) to end of study (day 12)</time_frame>
    <description>Overal Urine pH from 24h urine sample.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>24 hour urine phosphorus</measure>
    <time_frame>Change from baseline (Day 4) to initial start on treatment (Day 5)</time_frame>
    <description>Urine phosphorus</description>
  </primary_outcome>
  <primary_outcome>
    <measure>24 hour urine phosphorus</measure>
    <time_frame>Change from baseline (Day 4) to end of study (day 12)</time_frame>
    <description>Urine phosphorus</description>
  </primary_outcome>
  <primary_outcome>
    <measure>24 hour urine sulfate</measure>
    <time_frame>Change from baseline (Day 4) to initial start on treatment (Day 5)</time_frame>
    <description>Urine sulfate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>24 hour urine sulfate</measure>
    <time_frame>Change from baseline (Day 4) to end of study (day 12)</time_frame>
    <description>Urine sulfate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure># of patient who adherence to 100% Medication</measure>
    <time_frame>At the end of study approximately 10 weeks after start of study.</time_frame>
    <description>Patient's adherence to medication for duration of study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total out of pocket cost</measure>
    <time_frame>At the end of study approximately 10 weeks after start of study.</time_frame>
    <description>Calculate and compare treatment costs for the different interventions (in American dollars).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Satisfaction</measure>
    <time_frame>At the end of study approximately 10 weeks after start of study.</time_frame>
    <description>Patients Satisfaction Questionnaire Short Form (PSQ-18) measures patients satisfaction. Possible score range from 18 to 90 , with higher scores indicating a higher degree of satisfaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's GI Distress</measure>
    <time_frame>At the end of study approximately 10 weeks after start of study.</time_frame>
    <description>Patient's GI distress symptom scale measures patients GI distress. There are 18 questions with descriptive answers ranging from &quot;none&quot;, &quot;mild&quot;, &quot;moderate&quot;, &quot;quite a lot&quot; and &quot;unbearable&quot;. There are no numerical scores, rather just descriptive scores. &quot;None&quot; means no GI distress, &quot;unbearable&quot; means that you are in a lot of distress from your GI symptoms.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Kidney Stone</condition>
  <arm_group>
    <arm_group_label>Metabolic diet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Controlled metabolic diet arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Potassium citrate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium Bicarbonate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Litholyte arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Crystal Lite</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Potassium Bicarbonate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Potassium citrate</intervention_name>
    <description>Slow release potassium citrate UroCit-K. Participants will take 20mEq twice daily.</description>
    <arm_group_label>Crystal Lite</arm_group_label>
    <arm_group_label>Litholyte arm</arm_group_label>
    <arm_group_label>Metabolic diet</arm_group_label>
    <arm_group_label>Potassium Bicarbonate</arm_group_label>
    <arm_group_label>Potassium citrate</arm_group_label>
    <arm_group_label>Sodium Bicarbonate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium bicarbonate</intervention_name>
    <description>650mg tabs. Take 3 tabs twice daily.</description>
    <arm_group_label>Crystal Lite</arm_group_label>
    <arm_group_label>Litholyte arm</arm_group_label>
    <arm_group_label>Metabolic diet</arm_group_label>
    <arm_group_label>Potassium Bicarbonate</arm_group_label>
    <arm_group_label>Potassium citrate</arm_group_label>
    <arm_group_label>Sodium Bicarbonate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Litholyte</intervention_name>
    <description>One packet is taken with 170ml of water. Two packets daily.</description>
    <arm_group_label>Crystal Lite</arm_group_label>
    <arm_group_label>Litholyte arm</arm_group_label>
    <arm_group_label>Metabolic diet</arm_group_label>
    <arm_group_label>Potassium Bicarbonate</arm_group_label>
    <arm_group_label>Potassium citrate</arm_group_label>
    <arm_group_label>Sodium Bicarbonate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Crystal Lite</intervention_name>
    <description>The classic lemonade contains 21.7mEq/liter of alkali Therefore, patients will take 2 litres daily to have the 40mEq of alkali daily needed.</description>
    <arm_group_label>Crystal Lite</arm_group_label>
    <arm_group_label>Litholyte arm</arm_group_label>
    <arm_group_label>Metabolic diet</arm_group_label>
    <arm_group_label>Potassium Bicarbonate</arm_group_label>
    <arm_group_label>Potassium citrate</arm_group_label>
    <arm_group_label>Sodium Bicarbonate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults aged 18 and older.&#xD;
&#xD;
          -  with or without a history of stone disease.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  They are unable to take any of the medications due to health reasons.&#xD;
&#xD;
          -  Participants are pregnant or nursing.&#xD;
&#xD;
          -  Participants are unable to adhere to the metabolic diet.&#xD;
&#xD;
          -  Participants had a prior adverse event from one or more of the medications.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <reference>
    <citation>Scales CD Jr, Smith AC, Hanley JM, Saigal CS; Urologic Diseases in America Project. Prevalence of kidney stones in the United States. Eur Urol. 2012 Jul;62(1):160-5. doi: 10.1016/j.eururo.2012.03.052. Epub 2012 Mar 31.</citation>
    <PMID>22498635</PMID>
  </reference>
  <reference>
    <citation>Uribarri J, Oh MS, Carroll HJ. The first kidney stone. Ann Intern Med. 1989 Dec 15;111(12):1006-9. Review.</citation>
    <PMID>2688503</PMID>
  </reference>
  <reference>
    <citation>Pearle MS, Goldfarb DS, Assimos DG, Curhan G, Denu-Ciocca CJ, Matlaga BR, Monga M, Penniston KL, Preminger GM, Turk TM, White JR; American Urological Assocation. Medical management of kidney stones: AUA guideline. J Urol. 2014 Aug;192(2):316-24. doi: 10.1016/j.juro.2014.05.006. Epub 2014 May 20.</citation>
    <PMID>24857648</PMID>
  </reference>
  <reference>
    <citation>Pak CY, Sakhaee K, Fuller C. Successful management of uric acid nephrolithiasis with potassium citrate. Kidney Int. 1986 Sep;30(3):422-8.</citation>
    <PMID>3784284</PMID>
  </reference>
  <reference>
    <citation>Ryall RL. Urinary inhibitors of calcium oxalate crystallization and their potential role in stone formation. World J Urol. 1997;15(3):155-64. Review.</citation>
    <PMID>9228722</PMID>
  </reference>
  <reference>
    <citation>Preminger GM, Sakhaee K, Skurla C, Pak CY. Prevention of recurrent calcium stone formation with potassium citrate therapy in patients with distal renal tubular acidosis. J Urol. 1985 Jul;134(1):20-3.</citation>
    <PMID>4009822</PMID>
  </reference>
  <reference>
    <citation>Ettinger B, Pak CY, Citron JT, Thomas C, Adams-Huet B, Vangessel A. Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. J Urol. 1997 Dec;158(6):2069-73.</citation>
    <PMID>9366314</PMID>
  </reference>
  <reference>
    <citation>Preminger GM, Sakhaee K, Pak CY. Alkali action on the urinary crystallization of calcium salts: contrasting responses to sodium citrate and potassium citrate. J Urol. 1988 Feb;139(2):240-2.</citation>
    <PMID>3339718</PMID>
  </reference>
  <reference>
    <citation>Stern KL, Canvasser N, Borofsky M, Gleason VM, Kamphuis G, El Tayeb MM, Hsi R, Scotland KB. Alkalinizing Agents: A Review of Prescription, Over-the-Counter, and Medical Food Supplements. J Endourol. 2020 Jan;34(1):1-6. doi: 10.1089/end.2019.0292. Epub 2019 Sep 25. Review.</citation>
    <PMID>31333065</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 4, 2020</study_first_submitted>
  <study_first_submitted_qc>November 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2020</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Jodi Antonelli</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Calculi</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Potassium Citrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

